T2 Biosystems Inc. closed a $23 million series D funding round this week, which will support its ongoing development and clinical trials and the company inches closer to a FDA bid and commercialization.
This latest round was led by new investor Aisling Capital LLC, and joined by existing investors Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital and WS Investments.
In conjunction with the funding, Aisling Capital principal Dr. Josh Bilenker joins T2’s board of directors.